These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 12619225)
1. [Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)]. Harbeck N MMW Fortschr Med; 2003 Jan; 145(3-4):8, 10. PubMed ID: 12619225 [No Abstract] [Full Text] [Related]
2. [Prognostic factors in breast cancer patients]. Roisman I; Peretz T; Reznick AZ; Lifshitz I; Bitterman A; Fares F; Toledano H; Barzilay A; Durst AL Harefuah; 1996 May; 130(10):693-9. PubMed ID: 8794662 [No Abstract] [Full Text] [Related]
3. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]. Harbeck N; Thomssen C Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518 [TBL] [Abstract][Full Text] [Related]
4. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens. Thomssen C; Harbeck N; Dittmer J; Abraha-Spaeth SR; Papendick N; Paradiso A; Lisboa B; Jaenicke F; Schmitt M; Vetter M J Natl Cancer Inst; 2009 Jul; 101(14):1028-9. PubMed ID: 19535782 [No Abstract] [Full Text] [Related]
5. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Offersen BV; Pfeiffer P; Andreasen P; Overgaard J Lung Cancer; 2007 Apr; 56(1):43-50. PubMed ID: 17207889 [TBL] [Abstract][Full Text] [Related]
6. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Dowsett M; Dunbier AK Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018 [TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression. Lamy PJ; Verjat T; Servanton AC; Paye M; Leissner P; Mougin B Am J Clin Pathol; 2007 Sep; 128(3):404-13. PubMed ID: 17709314 [TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors in carcinoma of the breast. Thereupon depends success of the treatment]. Schneeweiss A; Thomssen Ch; Harbeck N; Bastert G MMW Fortschr Med; 2003 Jun; 145(24):34-6, 38. PubMed ID: 12866297 [TBL] [Abstract][Full Text] [Related]
9. Markers of the uPA system and common prognostic factors in breast cancer. Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278 [TBL] [Abstract][Full Text] [Related]
10. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728 [TBL] [Abstract][Full Text] [Related]
11. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Chautard D; Dalifard I; Chassevent A; Guyetant S; Daver A; Vielle B; Soret JY Urology; 2004 Jun; 63(6):1055-60. PubMed ID: 15183949 [TBL] [Abstract][Full Text] [Related]
13. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]. Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198 [TBL] [Abstract][Full Text] [Related]
14. Progression of breast tumors is accompanied by a decrease in expression of the Rho guanine exchange factor Tiam1. Stebel A; Brachetti C; Kunkel M; Schmidt M; Fritz G Oncol Rep; 2009 Jan; 21(1):217-22. PubMed ID: 19082465 [TBL] [Abstract][Full Text] [Related]
15. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Speleman L; Kerrebijn JD; Look MP; Meeuwis CA; Foekens JA; Berns EM Head Neck; 2007 Apr; 29(4):341-50. PubMed ID: 17163465 [TBL] [Abstract][Full Text] [Related]
17. Study indicates utility for new breast cancer prognostic marker. Stephenson J JAMA; 2001 Jun; 285(24):3077-8. PubMed ID: 11427119 [No Abstract] [Full Text] [Related]
18. Prognostic factors for breast cancer and their use in the clinical setting. Kapoor A; Vogel VG Expert Rev Anticancer Ther; 2005 Apr; 5(2):269-81. PubMed ID: 15877524 [TBL] [Abstract][Full Text] [Related]
19. [Minimal breast cancer: some prognostic signs]. Ermachenkova AM Vopr Onkol; 2013; 59(3):299-301. PubMed ID: 23909029 [No Abstract] [Full Text] [Related]
20. [erbB2 as a prognostic factor of breast cancers]. Nishimura R; Nagao K; Miyayama H Nihon Rinsho; 2000 Apr; 58 Suppl():407-12. PubMed ID: 11026025 [No Abstract] [Full Text] [Related] [Next] [New Search]